Price T Rowe Associates Inc Keros Therapeutics, Inc. Call Options Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding KROS
# of Institutions
157Shares Held
27.5MCall Options Held
28.7KPut Options Held
1.8K-
Black Rock Inc. New York, NY2.51MShares$167 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.76MShares$117 Million0.0% of portfolio
-
Alkeon Capital Management LLC New York, NY1.6MShares$106 Million0.12% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y91.53MShares$101 Million8.43% of portfolio
-
Orbimed Advisors LLC San Diego, CA1.27MShares$84.3 Million1.4% of portfolio
About Keros Therapeutics, Inc.
- Ticker KROS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,757,000
- Market Cap $1.71B
- Description
- Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...